Visfatin-induced lipid raft redox signaling platforms and dysfunction in glomerular endothelial cells

Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids

Volumn 1801, Issue 12, 2010, Pages 1294-1304

  Boini, Krishna M ^a   Zhang, Chun ^a   Xia, Min ^a   Han, Wei Qing ^a   Brimson, Christopher ^a   Poklis, Justin L ^a   Li, Pin Lan ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Adipokine; Free radical; Glomerulus; Lipid membrane microdomain; Redox regulation; Sphingolipid

Indexed keywords

ADIPONECTIN; AMITRIPTYLINE; CERAMIDE; FILIPIN; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE P47 PHOX; SMALL INTERFERING RNA; SPHINGOMYELIN PHOSPHODIESTERASE; SUPEROXIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL MEMBRANE PERMEABILITY; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOSKELETON; DOSE TIME EFFECT RELATION; ELECTRON SPIN RESONANCE; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; ENZYME ACTIVITY; GENE SILENCING; GLOMERULUS EPITHELIUM; LIPID RAFT; MALE; MICROTUBULE; NONHUMAN; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN LOCALIZATION; RAT;

ANIMALS; CELLS, CULTURED; CHROMATOGRAPHY, LIQUID; ELECTRON SPIN RESONANCE SPECTROSCOPY; GLOMERULAR MESANGIUM; LIPID METABOLISM; MICE; MICROSCOPY, CONFOCAL; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; OXIDATION-REDUCTION; SIGNAL TRANSDUCTION; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TANDEM MASS SPECTROMETRY;

EID: 77957970685     PISSN: 13881981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbalip.2010.09.001     Document Type: Article

References (63)

1. Weiss R., Dziura J., Burgert T.S., Tamborlane W.V., Taksali S.E., Yeckel C.W., Allen K., Lopes M., Savoye M., Morrison J., Sherwin R.S., Caprio S. Obesity and the metabolic syndrome in children and adolescents. N. Engl. J. Med. 2004, 350:2362-2374.
2. Yanovski S.Z., Yanovski J.A. Obesity. N. Engl. J. Med. 2002, 346:591-602.
3. Berg A.H., Combs T.P., Du X., Brownlee M., Scherer P.E. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat. Med. 2001, 7:947-953.
4. Yamauchi T., Kamon J., Waki H., Terauchi Y., Kubota N., Hara K., Mori Y., Ide T., Murakami K., Tsuboyama-Kasaoka N., Ezaki O., Akanuma Y., Gavrilova O., Vinson C., Reitman M.L., Kagechika H., Shudo K., Yoda M., Nakano Y., Tobe K., Nagai R., Kimura S., Tomita M., Froguel P., Kadowaki T. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat. Med. 2001, 7:941-946.
5. Ouchi N., Kihara S., Arita Y., Okamoto Y., Maeda K., Kuriyama H., Hotta K., Nishida M., Takahashi M., Muraguchi M., Ohmoto Y., Nakamura T., Yamashita S., Funahashi T., Matsuzawa Y. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation 2000, 102:1296-1301.
6. Stenvinkel P., Marchlewska A., Pecoits-Filho R., Heimburger O., Zhang Z., Hoff C., Holmes C., Axelsson J., Arvidsson S., Schalling M., Barany P., Lindholm B., Nordfors L. Adiponectin in renal disease: relationship to phenotype and genetic variation in the gene encoding adiponectin. Kidney Int. 2004, 65:274-281.
7. Iwashima Y., Horio T., Kumada M., Suzuki Y., Kihara S., Rakugi H., Kawano Y., Funahashi T., Ogihara T. Adiponectin and renal function, and implication as a risk of cardiovascular disease. Am. J. Cardiol. 2006, 98:1603-1608.
8. Qi L., Doria A., Manson J.E., Meigs J.B., Hunter D., Mantzoros C.S., Hu F.B. Adiponectin genetic variability, plasma adiponectin, and cardiovascular risk in patients with type 2 diabetes. Diabetes 2006, 55:1512-1516.
9. Fain J.N., Tagele B.M., Cheema P., Madan A.K., Tichansky D.S. Release of 12 adipokines by adipose tissue, nonfat cells, and fat cells from obese women. Obesity 2010, 18:890-896. (Silver.Spring).
10. Zoccali C., Mallamaci F., Tripepi G., Benedetto F.A., Cutrupi S., Parlongo S., Malatino L.S., Bonanno G., Seminara G., Rapisarda F., Fatuzzo P., Buemi M., Nicocia G., Tanaka S., Ouchi N., Kihara S., Funahashi T., Matsuzawa Y. Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J. Am. Soc. Nephrol. 2002, 13:134-141.
11. Sethi J.K., Vidal-Puig A. Visfatin: the missing link between intra-abdominal obesity and diabetes?. Trends Mol. Med. 2005, 11:344-347.
12. Samal B., Sun Y., Stearns G., Xie C., Suggs S., McNiece I. Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol. Cell. Biol. 1994, 14:1431-1437.
13. Pagano C., Pilon C., Olivieri M., Mason P., Fabris R., Serra R., Milan G., Rossato M., Federspil G., Vettor R. Reduced plasma visfatin/pre-B cell colony-enhancing factor in obesity is not related to insulin resistance in humans. J. Clin. Endocrinol. Metab. 2006, 91:3165-3170.
14. Revollo J.R., Grimm A.A., Imai S. The regulation of nicotinamide adenine dinucleotide biosynthesis by Nampt/PBEF/visfatin in mammals. Curr. Opin. Gastroenterol. 2007, 23:164-170.
15. de Luis D.A., Sagrado M.G., Aller R., Conde R., Izaola O. Circulating visfatin in obese non-diabetic patients in relation to cardiovascular risk factors, insulin resistance, and adipocytokines: a contradictory piece of the puzzle. Nutrition 2009, (Epub ahead of print).
16. Fukuhara A., Matsuda M., Nishizawa M., Segawa K., Tanaka M., Kishimoto K., Matsuki Y., Murakami M., Ichisaka T., Murakami H., Watanabe E., Takagi T., Akiyoshi M., Ohtsubo T., Kihara S., Yamashita S., Makishima M., Funahashi T., Yamanaka S., Hiramatsu R., Matsuzawa Y., Shimomura I. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005, 307:426-430.
17. Chen M.P., Chung F.M., Chang D.M., Tsai J.C., Huang H.F., Shin S.J., Lee Y.J. Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 2006, 91:295-299.
18. Haider D.G., Pleiner J., Francesconi M., Wiesinger G.F., Muller M., Wolzt M. Exercise training lowers plasma visfatin concentrations in patients with type 1 diabetes. J. Clin. Endocrinol. Metab. 2006, 91:4702-4704.
19. Bailey S.D., Loredo-Osti J.C., Lepage P., Faith J., Fontaine J., Desbiens K.M., Hudson T.J., Bouchard C., Gaudet D., Perusse L., Vohl M.C., Engert J.C. Common polymorphisms in the promoter of the visfatin gene (PBEF1) influence plasma insulin levels in a French-Canadian population. Diabetes 2006, 55:2896-2902.
20. Axelsson J., Witasp A., Carrero J.J., Qureshi A.R., Suliman M.E., Heimburger O., Barany P., Lindholm B., Alvestrand A., Schalling M., Nordfors L., Stenvinkel P. Circulating levels of visfatin/pre-B-cell colony-enhancing factor 1 in relation to genotype, GFR, body composition, and survival in patients with CKD. Am. J. Kidney Dis. 2007, 49:237-244.
21. Cheng K.H., Chu C.S., Lee K.T., Lin T.H., Hsieh C.C., Chiu C.C., Voon W.C., Sheu S.H., Lai W.T. Adipocytokines and proinflammatory mediators from abdominal and epicardial adipose tissue in patients with coronary artery disease. Int. J. Obes. (Lond.) 2008, 32:268-274.
22. Spiroglou S.G., Kostopoulos C.G., Varakis J.N., Papadaki H.H. Adipokines in periaortic and epicardial adipose tissue: differential expression and relation to atherosclerosis. J. Atheroscler. Thromb. 2010, 17:115-130.
23. Takebayashi K., Suetsugu M., Wakabayashi S., Aso Y., Inukai T. Association between plasma visfatin and vascular endothelial function in patients with type 2 diabetes mellitus. Metabolism 2007, 56:451-458.
24. van der Veer E., Nong Z., O'Neil C., Urquhart B., Freeman D., Pickering J.G. Pre-B-cell colony-enhancing factor regulates NAD+-dependent protein deacetylase activity and promotes vascular smooth muscle cell maturation. Circ. Res. 2005, 97:25-34.
25. Yilmaz M.I., Saglam M., Carrero J.J., Qureshi A.R., Caglar K., Eyileten T., Sonmez A., Cakir E., Yenicesu M., Lindholm B., Stenvinkel P., Axelsson J. Serum visfatin concentration and endothelial dysfunction in chronic kidney disease. Nephrol. Dial. Transplant. 2008, 23:959-965.
26. Zoccali C. Endothelial dysfunction in CKD: a new player in town?. Nephrol. Dial. Transplant. 2008, 23:783-785.
27. Sommer G., Garten A., Petzold S., Beck-Sickinger A.G., Bluher M., Stumvoll M., Fasshauer M. Visfatin/PBEF/Nampt: structure, regulation and potential function of a novel adipokine. Clin. Sci. (Lond.) 2008, 115:13-23.
28. Berndt J., Kloting N., Kralisch S., Kovacs P., Fasshauer M., Schon M.R., Stumvoll M., Bluher M. Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. Diabetes 2005, 54:2911-2916.
29. Axelsson J., Svensson J., Andersson-Engels S. Spatially varying regularization based on spectrally resolved fluorescence emission in fluorescence molecular tomography. Opt. Express 2007, 15:13574-13584.
30. Norman J.T., Fine L.G. Intrarenal oxygenation in chronic renal failure. Clin. Exp. Pharmacol. Physiol. 2006, 33:989-996.
31. Song H.K., Lee M.H., Kim B.K., Park Y.G., Ko G.J., Kang Y.S., Han J.Y., Han S.Y., Han K.H., Kim H.K., Cha D.R. Visfatin: a new player in mesangial cell physiology and diabetic nephropathy. Am. J. Physiol. Renal Physiol. 2008, 295:F1485-F1494.
32. Van Beijnum J.R., Moerkerk P.T., Gerbers A.J., De Bruine A.P., Arends J.W., Hoogenboom H.R., Hufton S.E. Target validation for genomics using peptide-specific phage antibodies: a study of five gene products overexpressed in colorectal cancer. Int. J. Cancer 2002, 101:118-127.
33. Zhang A.Y., Yi F., Jin S., Xia M., Chen Q.Z., Gulbins E., Li P.L. Acid sphingomyelinase and its redox amplification in formation of lipid raft redox signaling platforms in endothelial cells. Antioxid. Redox Signal. 2007, 9:817-828.
34. Adler S., Eng B. Integrin receptors and function on cultured glomerular endothelial cells. Kidney Int. 1993, 44:278-284.
35. Zhang A.Y., Yi F., Zhang G., Gulbins E., Li P.L. Lipid raft clustering and redox signaling platform formation in coronary arterial endothelial cells. Hypertension 2006, 47:74-80.
36. Jin S., Zhang Y., Yi F., Li P.L. Critical role of lipid raft redox signaling platforms in endostatin-induced coronary endothelial dysfunction. Arterioscler. Thromb. Vasc. Biol. 2008, 28:485-490.
37. Fillet M., Van Heugen J.C., Servais A.C., De Graeve J., Crommen J. Separation, identification and quantitation of ceramides in human cancer cells by liquid chromatography-electrospray ionization tandem mass spectrometry. J. Chromatogr. A 2002, 949:225-233.
38. Yi F., Zhang A.Y., Janscha J.L., Li P.L., Zou A.P. Homocysteine activates NADH/NADPH oxidase through ceramide-stimulated Rac GTPase activity in rat mesangial cells. Kidney Int. 2004, 66:1977-1987.
39. Zhang C., Hu J.J., Xia M., Boini K.M., Brimson C., Li P.L. Redox signaling via lipid raft clustering in homocysteine-induced injury of podocytes. Biochim. Biophys. Acta 2010, 1803:482-491.
40. Ying C.J., Xu J.W., Ikeda K., Takahashi K., Nara Y., Yamori Y. Tea polyphenols regulate nicotinamide adenine dinucleotide phosphate oxidase subunit expression and ameliorate angiotensin II-induced hyperpermeability in endothelial cells. Hypertens. Res. 2003, 26:823-828.
41. Hordijk P.L., Anthony E., Mul F.P., Rientsma R., Oomen L.C., Roos D. Vascular-endothelial-cadherin modulates endothelial monolayer permeability. J. Cell Sci. 1999, 112(Pt 12):1915-1923.
42. Jin S., Yi F., Li P.L. Contribution of lysosomal vesicles to the formation of lipid raft redox signaling platforms in endothelial cells. Antioxid. Redox Signal. 2007, 9:1417-1426.
43. Bollinger C.R., Teichgraber V., Gulbins E. Ceramide-enriched membrane domains. Biochim. Biophys. Acta 2005, 1746:284-294.
44. Li Y., Zhang Y., Dorweiler B., Cui D., Wang T., Woo C.W., Brunkan C.S., Wolberger C., Imai S., Tabas I. Extracellular Nampt promotes macrophage survival via a nonenzymatic interleukin-6/STAT3 signaling mechanism. J. Biol. Chem. 2008, 283:34833-34843.
45. Gulbins E. Regulation of death receptor signaling and apoptosis by ceramide. Pharmacol. Res. 2003, 47:393-399.
46. Dbaibo G.S., Hannun Y.A. Signal transduction and the regulation of apoptosis: roles of ceramide. Apoptosis 1998, 3:317-334.
47. Kaushal G.P., Singh A.B., Shah S.V. Identification of gene family of caspases in rat kidney and altered expression in ischemia-reperfusion injury. Am. J. Physiol. 1998, 274:F587-F595.
48. Ueda N., Kaushal G.P., Shah S.V. Apoptotic mechanisms in acute renal failure. Am. J. Med. 2000, 108:403-415.
49. Yin T., Sandhu G., Wolfgang C.D., Burrier A., Webb R.L., Rigel D.F., Hai T., Whelan J. Tissue-specific pattern of stress kinase activation in ischemic/reperfused heart and kidney. J. Biol. Chem. 1997, 272:19943-19950.
50. Kaushal G.P., Ueda N., Shah S.V. Role of caspases (ICE/CED 3 proteases) in DNA damage and cell death in response to a mitochondrial inhibitor, antimycin A. Kidney Int. 1997, 52:438-445.
51. Peralta S.A., Mullin J.M., Knudsen K.A., Marano C.W. Tissue remodeling during tumor necrosis factor-induced apoptosis in LLC-PK1 renal epithelial cells. Am. J. Physiol. 1996, 270:F869-F879.
52. Gulbins E., Grassme H. Ceramide and cell death receptor clustering. Biochim. Biophys. Acta 2002, 1585:139-145.
53. Grassme H., Jendrossek V., Bock J., Riehle A., Gulbins E. Ceramide-rich membrane rafts mediate CD40 clustering. J. Immunol. 2002, 168:298-307.
54. Lassegue B., Clempus R.E. Vascular NAD(P)H oxidases: specific features, expression, and regulation. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2003, 285:R277-R297.
55. Dewas C., Dang P.M., Gougerot-Pocidalo M.A., El Benna J. TNF-alpha induces phosphorylation of p47(phox) in human neutrophils: partial phosphorylation of p47phox is a common event of priming of human neutrophils by TNF-alpha and granulocyte-macrophage colony-stimulating factor. J. Immunol. 2003, 171:4392-4398.
56. Landmesser U., Cai H., Dikalov S., McCann L., Hwang J., Jo H., Holland S.M., Harrison D.G. Role of p47(phox) in vascular oxidative stress and hypertension caused by angiotensin II. Hypertension 2002, 40:511-515.
57. Patterson C., Ruef J., Madamanchi N.R., Barry-Lane P., Hu Z., Horaist C., Ballinger C.A., Brasier A.R., Bode C., Runge M.S. Stimulation of a vascular smooth muscle cell NAD(P)H oxidase by thrombin. Evidence that p47(phox) may participate in forming this oxidase in vitro and in vivo. J. Biol. Chem. 1999, 274:19814-19822.
58. Simionescu M. Implications of early structural-functional changes in the endothelium for vascular disease. Arterioscler. Thromb. Vasc. Biol. 2007, 27:266-274.
59. Lum H., Roebuck K.A. Oxidant stress and endothelial cell dysfunction. Am. J. Physiol. Cell Physiol. 2001, 280:C719-C741.
60. Seeger W., Hansen T., Rossig R., Schmehl T., Schutte H., Kramer H.J., Walmrath D., Weissmann N., Grimminger F., Suttorp N. Hydrogen peroxide-induced increase in lung endothelial and epithelial permeability-effect of adenylate cyclase stimulation and phosphodiesterase inhibition. Microvasc. Res. 1995, 50:1-17.
61. Bernhard D., Csordas A., Henderson B., Rossmann A., Kind M., Wick G. Cigarette smoke metal-catalyzed protein oxidation leads to vascular endothelial cell contraction by depolymerization of microtubules. FASEB J. 2005, 19:1096-1107.
62. Tzima E. Role of small GTPases in endothelial cytoskeletal dynamics and the shear stress response. Circ. Res. 2006, 98:176-185.
63. Birukova A.A., Birukov K.G., Adyshev D., Usatyuk P., Natarajan V., Garcia J.G., Verin A.D. Involvement of microtubules and Rho pathway in TGF-beta1-induced lung vascular barrier dysfunction. J. Cell. Physiol. 2005, 204:934-947.